Home > Riviste > The Journal of Cardiovascular Surgery > Fascicoli precedenti > The Journal of Cardiovascular Surgery 2014 October;55(5) > The Journal of Cardiovascular Surgery 2014 October;55(5):631-40

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti

 

  LATEST DEVELOPMENTS IN THE TREATMENT OF CRITICAL LIMB ISCHEMIA 

The Journal of Cardiovascular Surgery 2014 October;55(5):631-40

Copyright © 2014 EDIZIONI MINERVA MEDICA

lingua: Inglese

Antiplatelet therapy in critical limb ischemia: update on clopidogrel and cilostazol

Spiliopoulos S.

Department of Interventional Radiology, Patras University Hospital, Patras, Greece


PDF


Antiplatelet therapy is essential for critical limb ischemia (CLI) patients, both as primary prevention for ischemic events and as adjuvant pharmacotherapy in order to avoid acute or late thrombo-occlusive events and maintain patency following peripheral endovascular or open surgical limb-salvage revascularization procedures. According to currently updated international guidelines clopidogrel as monotherapy or as part of dual antiplatelet therapy is recommended in CLI patients, while recent evidence delineated the beneficial effect of cilostazol in patients undergoing peripheral endovascular angioplasty or stenting as its administration resulted in a decrease of restenosis and clinically-driven reinterventions, as well as in the enhancement of platelet inhibition. This review aims in discussing recent evidence on the topic of antiplatelet therapy in CLI patients, with a special focus on the use of clopidogrel and cilostazol.

inizio pagina